Perhaps chemist, if you believe that DECN is going to market the GenPrecis system themselves. I for one don't believe that. I also know that a well noted big box has already dropped hints about an exclusive contract for GenPrecis and to help pay for its development. This is sometimes called pre-market concept testing. When you've spent the last 40 years doing this kind of stuff, prospective clients actually take note of what is said. Prospective clients are not in the "what have you done for me today" mode of penny stock traders.
Oh and by the way, and I know this will not be of any interest to people who are only interested in share price, but GenPrecis will actually provider answers to one of the industry's few enduring mysteries and IMO will become a Harvard Business School case study. More about this later. Maybe.
And one final thing, the huge revenue growth ahead will come from two sources IMO. GenChoice and the selling combination of GenChoice and GenUltimate.
(2)
(1)
Decision Diagnostics Corp (DECN) Stock Research Links